SG11202010499UA - Anti-cxcl13 antibodies for treating autoimmune diseases and cancer - Google Patents
Anti-cxcl13 antibodies for treating autoimmune diseases and cancerInfo
- Publication number
- SG11202010499UA SG11202010499UA SG11202010499UA SG11202010499UA SG11202010499UA SG 11202010499U A SG11202010499U A SG 11202010499UA SG 11202010499U A SG11202010499U A SG 11202010499UA SG 11202010499U A SG11202010499U A SG 11202010499UA SG 11202010499U A SG11202010499U A SG 11202010499UA
- Authority
- SG
- Singapore
- Prior art keywords
- cancer
- autoimmune diseases
- treating autoimmune
- cxcl13 antibodies
- cxcl13
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6854—Immunoglobulins
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/52—Assays involving cytokines
- G01N2333/521—Chemokines
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Hematology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Biophysics (AREA)
- Cell Biology (AREA)
- Genetics & Genomics (AREA)
- Diabetes (AREA)
- Biotechnology (AREA)
- Analytical Chemistry (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Microbiology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Physical Education & Sports Medicine (AREA)
- Obesity (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2018106158 | 2018-09-18 | ||
| PCT/CN2019/106409 WO2020057540A1 (en) | 2018-09-18 | 2019-09-18 | Anti-cxcl13 antibodies for treating autoimmune diseases and cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202010499UA true SG11202010499UA (en) | 2020-11-27 |
Family
ID=69888374
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202010499UA SG11202010499UA (en) | 2018-09-18 | 2019-09-18 | Anti-cxcl13 antibodies for treating autoimmune diseases and cancer |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US11028164B2 (en) |
| EP (1) | EP3713957A4 (en) |
| JP (1) | JP7098854B2 (en) |
| KR (1) | KR20200106056A (en) |
| CN (1) | CN112469735B (en) |
| AU (2) | AU2019342180B2 (en) |
| BR (1) | BR112021000583A2 (en) |
| CA (1) | CA3098509A1 (en) |
| EA (1) | EA202092162A1 (en) |
| IL (1) | IL281441B2 (en) |
| MX (1) | MX2021002605A (en) |
| SG (1) | SG11202010499UA (en) |
| WO (1) | WO2020057540A1 (en) |
| ZA (1) | ZA202100080B (en) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20230192824A1 (en) * | 2020-04-02 | 2023-06-22 | United States Of America As Represented By The Secretary Of The Navy | Antigen Binding Proteins to Class 5 ETEC Adhesins |
| US20230348571A1 (en) * | 2020-04-06 | 2023-11-02 | Vanderbilt University | Cross-reactive coronavirus antibodies and uses thereof |
| CN116782930A (en) | 2020-06-11 | 2023-09-19 | 瓦西尼斯公司 | Use of CXCL13 binding molecules to promote peripheral nerve regeneration |
| US20240059762A1 (en) * | 2020-12-18 | 2024-02-22 | Single Cell Technology, Inc. | Anti-sars coronavirus-2 nucleocapsid protein antibodies |
| WO2022182562A1 (en) * | 2021-02-23 | 2022-09-01 | BioLegend, Inc. | ANTI-SARS-CoV-2 SPIKE GLYCOPROTEIN S1 AGENTS AND COMPOSITIONS |
| CN113234137B (en) * | 2021-06-21 | 2022-02-25 | 华中农业大学 | Application of CXCL20a protein isolated from grass carp as antibacterial peptide |
| WO2023196588A2 (en) * | 2022-04-08 | 2023-10-12 | Beam Therapeutics Inc. | Hemoglobin g-makassar binding polypeptides and antibodies and methods of using the same |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7919083B2 (en) * | 2002-11-15 | 2011-04-05 | Morehouse School Of Medicine | Anti-chemokine and associated receptors antibodies for inhibition of growth of neoplasms |
| US8512701B2 (en) * | 2002-11-15 | 2013-08-20 | Morehouse School Of Medicine | Anti-CXCL13 and anti-CXCR5 antibodies for the prevention and treatment of cancer and cancer cell migration |
| CA2501422C (en) * | 2004-04-29 | 2014-08-12 | University Of Rochester | Lymphoid chemokines in the diagnosis, monitoring and treatment of autoimmune disease |
| BRPI0710636A2 (en) * | 2006-04-21 | 2011-08-23 | Centocor Inc | cxcl 31 antagonists and their use in the treatment of inflammatory diseases |
| US20080227704A1 (en) | 2006-12-21 | 2008-09-18 | Kamens Joanne S | CXCL13 binding proteins |
| US20080199481A1 (en) * | 2007-02-21 | 2008-08-21 | Astrazeneca Ab | Compounds |
| WO2012031099A2 (en) | 2010-09-02 | 2012-03-08 | Vaccinex, Inc. | Anti-cxcl13 antibodies and methods of using the same |
| EP2820045B1 (en) * | 2012-03-02 | 2018-08-22 | Vaccinex, Inc. | Methods for the treatment of b cell-mediated inflammatory diseases |
| CN105408355A (en) * | 2013-01-31 | 2016-03-16 | 瓦克纳斯有限公司 | Methods for increasing immunoglobulin A levels |
| US20160002325A1 (en) * | 2013-03-08 | 2016-01-07 | Vaccinex, Inc. | Anti-cxcl13 antibodies and associated epitope sequences |
-
2019
- 2019-09-18 KR KR1020207022061A patent/KR20200106056A/en not_active Application Discontinuation
- 2019-09-18 MX MX2021002605A patent/MX2021002605A/en unknown
- 2019-09-18 SG SG11202010499UA patent/SG11202010499UA/en unknown
- 2019-09-18 CN CN201980046759.4A patent/CN112469735B/en active Active
- 2019-09-18 CA CA3098509A patent/CA3098509A1/en not_active Abandoned
- 2019-09-18 BR BR112021000583-8A patent/BR112021000583A2/en unknown
- 2019-09-18 WO PCT/CN2019/106409 patent/WO2020057540A1/en unknown
- 2019-09-18 US US16/963,130 patent/US11028164B2/en active Active
- 2019-09-18 EP EP19863616.9A patent/EP3713957A4/en active Pending
- 2019-09-18 AU AU2019342180A patent/AU2019342180B2/en not_active Ceased
- 2019-09-18 EA EA202092162A patent/EA202092162A1/en unknown
- 2019-09-18 JP JP2020536028A patent/JP7098854B2/en active Active
-
2021
- 2021-01-05 ZA ZA2021/00080A patent/ZA202100080B/en unknown
- 2021-03-11 IL IL281441A patent/IL281441B2/en unknown
- 2021-05-20 US US17/326,019 patent/US20210284724A1/en active Pending
- 2021-11-05 AU AU2021261971A patent/AU2021261971A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US20210284724A1 (en) | 2021-09-16 |
| EP3713957A1 (en) | 2020-09-30 |
| AU2019342180B2 (en) | 2021-08-05 |
| IL281441B (en) | 2022-10-01 |
| IL281441B2 (en) | 2023-02-01 |
| WO2020057540A8 (en) | 2020-07-23 |
| CN112469735A (en) | 2021-03-09 |
| MX2021002605A (en) | 2021-07-21 |
| IL281441A (en) | 2021-04-29 |
| JP2021513324A (en) | 2021-05-27 |
| CN112469735B (en) | 2022-11-08 |
| JP7098854B2 (en) | 2022-07-12 |
| WO2020057540A1 (en) | 2020-03-26 |
| AU2019342180A1 (en) | 2020-07-16 |
| EP3713957A4 (en) | 2021-08-18 |
| KR20200106056A (en) | 2020-09-10 |
| US20200399360A1 (en) | 2020-12-24 |
| AU2021261971A1 (en) | 2021-12-16 |
| BR112021000583A2 (en) | 2021-04-06 |
| US11028164B2 (en) | 2021-06-08 |
| CA3098509A1 (en) | 2020-03-26 |
| ZA202100080B (en) | 2022-06-29 |
| EA202092162A1 (en) | 2021-07-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL281441B (en) | Anti-cxcl13 antibodies for treating autoimmune diseases and cancer | |
| ZA202002923B (en) | Cd47 antibodies and uses thereof for treating cancer | |
| IL267803A (en) | Methods of treating cancer with anti-tim-3 antibodies | |
| IL276164A (en) | Anti-tmprss2 antibodies and antigen-binding fragments | |
| IL281449A (en) | Anti-ifnar1 antibodies for treating autoimmune diseases | |
| IL276303A (en) | Methods for treating cancer with anti-pd-1 antibodies | |
| IL289663A (en) | Claudin18 antibodies and methods of treating cancer | |
| IL276446A (en) | Methods of selecting and designing safer and more effective anti-ctla-4 antibodies for cancer therapy | |
| IL273196A (en) | Claudin6 antibodies and methods of treating cancer | |
| IL277861A (en) | Axl-specific antibodies for cancer treatment | |
| IL275940A (en) | Combination therapy with anti-il-8 antibodies and anti-pd-1 antibodies for treating cancer | |
| IL286297A (en) | Methods of treating minimal residual cancer | |
| IL274766A (en) | Humanized anti-liv1 antibodies for the treatment of breast cancer | |
| IL282478A (en) | Materials and methods for treating cancer | |
| IL265178A (en) | Antibody for treating autoimmune diseases | |
| SG11202005296SA (en) | Combination therapy between anti-progastrin antibody and immunotherapy to treat cancer | |
| IL282308A (en) | Novel cancer antigens and methods | |
| EP3833323A4 (en) | Compositions and methods for treating cancer and autoimmune diseases | |
| IL280421A (en) | Cancer treatment with an antibody | |
| GB201810635D0 (en) | Peptides and cancer treatment | |
| GB201813138D0 (en) | Cancer treatment with an antibody | |
| GB201819026D0 (en) | Means and methods for treating cancer | |
| GB201903012D0 (en) | Antibodies for treatment of cancer and other diseases | |
| GB201909135D0 (en) | Means and methods for treating cancer |